Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

including obesity. The Phase 2b results for the drug, monlunabant, were tucked into Novo Nordisk’s report of full-year 2024 financial results released Wednesday. The company said the once-daily ...

The company predicted operating profit for 2025 to climb between 19% and 27%, compared to growth of 26% last year.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the ...